DIDOX EXHIBITS ANTIVIRAL ACTIVITY IN A RETROVIRUS ANIMAL MODEL (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


DIDOX EXHIBITS ANTIVIRAL ACTIVITY IN A RETROVIRUS ANIMAL MODEL (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2383 1992. Unique Identifier : AIDSLINE ICDB/92685653
Mills DL; Elford HL; van't Riet B; Webb SR; Biology Dept., Virginia Commonwealth Univ., Richmond, VA 23284

Abstract: Didox, a ribonucleotide reductase inhibitor, currently in clinical trials based on its anticancer activity in animal tumor models, was tested in a retrovirus murine model to determine the requirement for deoxynucleotide synthesis for retrovirus replication and to investigate the potential of Didox to enhance the effectiveness of deoxynucleoside analogs in combination protocols for retrovirus-induced diseases like AIDS. Mice infected with the Friend leukemia virus (FLV) complex were treated with Didox for 12 days. The mice were sacrificed on day 14, and the degree of splenomegaly was measured to indicate the amount of FLV replication (viremia). In addition, the blood cell profile was examined. FLV infection caused an 8-fold increase in spleen wt and a 4-fold increase in reticulocytes. Both increases were completely prevented by the optimum dose of Didox. These results indicate a potential for Didox in retroviral-caused disease.
Keywords: Animal Antiviral Agents/*THERAPEUTIC USE Friend Virus/DRUG EFFECTS/*PHYSIOLOGY/*PATHOGENICITY Leukemia, Experimental/*PREVENTION & CONTROL Mice Reticulocytes/DRUG EFFECTS/PATHOLOGY Ribonucleotide Reductases/ANTAGONISTS & INHIB Splenomegaly/PREVENTION & CONTROL Virus Replication/*DRUG EFFECTS ABSTRACTKWDanimalantiviralagents/KWDtherapeuticusefriendvirus/drugeffects/KWDphysiology/KWDpathogenicityleukemia,experimental/KWDprevention&controlmicereticulocytes/drugeffects/pathologyribonucleotidereductases/antagonists&inhibsplenomegaly/prevention&controlvirusreplication/KWDdrugeffectsabstract
920930
M9290908

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .